Jeito Capital is building a strong and diversified portfolio in Biotech and innovative medical companies.
Neogene TherapeuticsOncology - Cell Therapy
Round of €93 million
Sparing VisionOphtalmology - Gene Therapy
Round of €44,5 million
innoSkelRare bone Diseases - Gene Therapy
Round of €20 million
PulmocideInhaled Respiratory Medicine
Round of €75 million
Alentis TherapeuticsFibrotic Diseases Medicine
Round of €55 million
Quell TherapeuticsT-reg cell therapy in auto-immune and inflammatory diseases
Round of €138 million
Oncology – Cell therapy
Round of €93 million – September 2020
Negoene is a preclinical biotechnology company at the forefront of developing next-generation, fully personalized T-cell therapies targeting a wide range of cancers.
Ophtalmology – Gene Therapy
Round of €44,5 million – September 2020
SparingVision is specialized in the research and development of ophthalmic treatments, particularly in the field of hereditary retinal degeneration.
Rare bone diseases – Gene therapy
Round of €20 million – December 2020
Innoskel is a French biotech company focused on the development of genetic therapies for rare skeletal diseases that can cause dwarfism and severe deformities.
Inhaled respiratory medicine
Round of €75 million – May 2021
Pulmocide is a UK-based biotech developing a leading range of first-in-class inhaled anti-infectives for the targeted treatment of life-threatening lung infections.
Fibrotic diseases medicine
Round of €55 million – June 2021
Alentis Therapeutics is a Swiss-based biotech with R&D activities in France that focuses on the development of highly innovative treatments for fibrotic diseases using monoclonal antibodies targeting Claudin-1.
T-reg cell therapy in auto-immune and inflammatory diseases
Round of €138 million – November 2021
Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.
At a glance